IP Library Granted Patent US 8,715,960
Granted Patent B2
US 8,715,960 · App. 13/260,497 · Granted May 6, 2014

Aberrant mitochondrial DNA, associated fusion transcripts and translation products and hybridization probes therefor

Inventors: Ryan Parr (Thunder Bay, CA); Gabriel Dakubo (Thunder Bay, CA); Andrew Harbottle (Newcastle Upon Tyne, GB); Brian Reguly (Vancouver, CA); Jennifer Creed (Broomfield, CO); Kerry Robinson (Thunder Bay, CA); Daniel Klein (Thunder Bay, CA)
Assignee: Mitomics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,960
App. No.
13/260,497
Granted
May 6, 2014
Kind
B2
Abstract

The present invention provides novel mitochondrial fusion transcripts, the parent mutated mtDNA molecules, and the resulting translation products (proteins) for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided.

Claims (10)

1. A method of detecting a cancer in a mammal, the method comprising assaying a biological sample from the mammal for the presence of at least one mitochondrial fusion protein, the protein having an amino acid sequence resulting from the translation of a mitochondrial fusion transcript corresponding to a mutation in mitochondrial DNA, wherein the amino acid sequence is set forth in SEQ ID NO: 58.

2. The method of claim 1 , wherein the cancer is prostate cancer, testicular cancer, ovarian cancer, breast cancer, colorectal cancer, lung cancer or melanoma skin cancer.

3. The method of claim 1 , wherein said assay comprises an immunological assay.

4. The method of claim 3 , wherein said assay is conducted using an antibody or antigen-binding fragment thereof having a specificity to an isolated mitochondrial fusion protein having an amino acid sequence as set forth in SEQ ID NO: 58.

5. The method of claim 1 , wherein the biological sample is obtained from a subject suspected of having one of prostate cancer, testicular cancer, ovarian cancer, breast cancer, colorectal cancer, lung cancer or melanoma skin cancer.

6. The method of claim 5 , wherein the biological sample is a tissue or fluid.

7. The method of claim 6 , wherein the tissue is skin, lung, breast, prostate, nervous, muscle, heart, stomach, colon or rectal tissue.

8. The method of claim 6 , wherein the fluid is blood, saliva, cerebral spinal fluid, sputa, urine, mucous, synovial fluid, peritoneal fluid or amniotic fluid.

9. The method of claim 1 , wherein the cancer is prostate cancer.

10. The method of claim 1 , wherein the biological sample is prostate tissue.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: DODICK LANDAU INC AS COURT APPOINTED RECEIVER OF MITOMICS INC.
To: MDNA LIFE SCIENCES INC.
Reel/Frame 041335/0895 →
CHANGE OF NAME Recorded Dec 5, 2011
From: GENESIS GENOMICS INC.
To: MITOMICS INC.
Reel/Frame 027324/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2011
From: PARR, RYAN; DAKUBO, GABRIEL; HARBOTTLE, ANDREW; REGULY, BRIAN; CREED, JENNIFER; ROBINSON, KERRY; KLEIN, DANIEL
To: GENESIS GENOMICS INC.
Reel/Frame 026983/0152 →
Continuity (3)
Continuation In Part PCTCA2009000351 · Mar 27, 2009
Provisional Application 61040616 · Mar 28, 2008
Related Publication 20130059299A1 · Mar 7, 2013